Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2/3 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 288Gynecologic 18CNS 9Sarcoma 7Genitourinary 7Gastrointestinal 7Endocrine 3Tumor-Agnostic 2Thoracic 2Lymphoid 2Head & Neck 2Dermatologic 2Other solid neoplasm 1Other 1NET 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Hodgkin Disease 1Breast Neoplasms 1

Interventions

Rituximab 1371Cyclophosphamide 1297Vincristine 662Doxorubicin 583Etoposide 525Prednisone 505Cytarabine 481fludarabine 462Methotrexate 441Dexamethasone 411fludarabine phosphate 396Lenalidomide 347Filgrastim 342Bendamustine Hydrochloride 274Radiotherapy 266venetoclax 255ibrutinib 249Peripheral Blood Stem Cell Transplantation 233Melphalan 229obinutuzumab 228Granulocyte Colony-Stimulating Factor 212Bortezomib 204Gemcitabine 201Busulfan 186Whole-Body Irradiation 185Mycophenolic Acid 174Tacrolimus 164Specimen Handling 161Calcium Dobesilate 150Magnetic Resonance Spectroscopy 149

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Tamoxifen × Lymphoid × Clear all
NCT06355401 2024-04-09

Maintenance Hormonal Therapy and DLBCL

Sohag University

Phase 2/3 Not yet recruiting
100 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT00165308 2014-07-09

Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors

Dana-Farber Cancer Institute

Phase NA Completed
29 enrolled
BreastLymphoid

Breast Neoplasms, Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡